The patent describes the use of low concentration hypochlorous acid solutions to inhibit viral and bacterial activity, providing a potential solution for disinfection and disease prevention.
- A method of treating disease states associated with increased microbial activity by delivering an aqueous antiseptic solution to a patient through a vaping device. - The aqueous antiseptic solution contains hypochlorous acid heated to approximately 100-250°C and has a pH range of approximately 6.1 to 6.3. - The method involves administering atomized particles of the antiseptic solution through a mouthpiece into the upper respiratory tract for a prescribed duration. - The particles range in size from approximately 0.1 μm to 99 μm. - The method can be used to treat respiratory, ophthalmic, and cochlear illnesses caused by microbial, viral, fungal, or allergy-causing agents. - The technology described in the document is not limited to the specific embodiments mentioned and can be applied in various combinations. - The document provides priority applications, related child applications, and family applications related to the disclosed technology. - The document also includes legal events related to the patent application process.
This is from US20200281969A1 in 2024 at this link.
The top five keywords in the document are: 1. Hypochlorous acid 2. Inhibiting 3. Viral 4. Bacterial 5. Low concentration
Inhibiting viral and bacterial activity using low concentration hypochlorous acid solutions Download PDF
Info
Publication number US20200281969A1 US20200281969A1 US16/293,551 US201916293551A US2020281969A1 US 20200281969 A1 US20200281969 A1 US 20200281969A1 US 201916293551 A US201916293551 A US 201916293551A US 2020281969 A1 US2020281969 A1 US 2020281969A1 Authority US United States Prior art keywords approximately antiseptic solution Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Abandoned
Application number
US16/293,551
Inventor
John Burd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wonder Spray LLC
Original Assignee
Wonder Spray LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
2019-03-05 Application filed by Wonder Spray LLC filed Critical Wonder Spray LLC
2019-03-05 Priority to US16/293,551 priority Critical patent/US20200281969A1/en
2019-03-25 Assigned to Wonder Spray, LLC reassignment Wonder Spray, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BURD, JOHN
2019-07-03 Priority to US16/503,397 priority patent/US20200281970A1/en
2020-03-05 Priority to PCT/US2020/021268 priority patent/WO2020181138A1/en
2020-03-27 Priority to US16/833,209 priority patent/US20200281971A1/en
2020-09-10 Publication of US20200281969A1 publication Critical patent/US20200281969A1/en
2021-02-18 Priority to US17/179,251 priority patent/US20210177892A1/en
2021-11-03 Priority to US17/518,452 priority patent/US20220054539A1/en
2022-06-27 Priority to US17/850,003 priority patent/US20220323489A1/en
Status Abandoned legal-status Critical Current
Links
- USPTO PatentCenter
- USPTO Assignment
- Global Dossier
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 title claims abstract description 147
- 230000003612 virological effect Effects 0.000 title description 15
- 230000001580 bacterial effect Effects 0.000 title description 4
- 230000002401 inhibitory effect Effects 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 241000894006 Bacteria Species 0.000 claims abstract description 11
- 230000000241 respiratory effect Effects 0.000 claims abstract description 8
- 241000233866 Fungi Species 0.000 claims abstract description 7
- 241000700605 Viruses Species 0.000 claims abstract description 7
- 102000029797 Prion Human genes 0.000 claims abstract description 5
- 108091000054 Prion Proteins 0.000 claims abstract description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 5
- 230000000813 microbial effect Effects 0.000 claims description 28
- 230000002421 anti-septic effect Effects 0.000 claims description 26
- 239000002245 particle Substances 0.000 claims description 15
- 241000588724 Escherichia coli Species 0.000 claims description 9
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 4
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims description 4
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 3
- 244000063299 Bacillus subtilis Species 0.000 claims description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 3
- 241000588914 Enterobacter Species 0.000 claims description 3
- 241000588697 Enterobacter cloacae Species 0.000 claims description 3
- 241000194032 Enterococcus faecalis Species 0.000 claims description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 3
- 241000186779 Listeria monocytogenes Species 0.000 claims description 3
- 241000588767 Proteus vulgaris Species 0.000 claims description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 3
- 241001138501 Salmonella enterica Species 0.000 claims description 3
- 241000607762 Shigella flexneri Species 0.000 claims description 3
- 241000607447 Yersinia enterocolitica Species 0.000 claims description 3
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 3
- 229940007042 proteus vulgaris Drugs 0.000 claims description 3
- 229940098232 yersinia enterocolitica Drugs 0.000 claims description 3
- 239000007921 spray Substances 0.000 abstract description 16
- 239000006199 nebulizer Substances 0.000 abstract description 14
- 229940051866 mouthwash Drugs 0.000 abstract description 10
- 239000000243 solution Substances 0.000 description 63
- 239000007864 aqueous solution Substances 0.000 description 33
- 239000003795 chemical substances by application Substances 0.000 description 22
- 239000004599 antimicrobial Substances 0.000 description 18
- 210000000214 mouth Anatomy 0.000 description 17
- 206010020751 Hypersensitivity Diseases 0.000 description 16
- 208000026935 allergic disease Diseases 0.000 description 16
- 230000002538 fungal effect Effects 0.000 description 14
- 230000002685 pulmonary effect Effects 0.000 description 12
- 239000000443 aerosol Substances 0.000 description 11
- 239000003595 mist Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 230000000845 anti-microbial effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 239000000645 desinfectant Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 6
- 230000029058 respiratory gaseous exchange Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000002716 delivery method Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000000758 acidotic effect Effects 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000000889 atomisation Methods 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000006193 liquid solution Substances 0.000 description 3
- 239000007922 nasal spray Substances 0.000 description 3
- 229940097496 nasal spray Drugs 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 201000008197 Laryngitis Diseases 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 229940113601 irrigation solution Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- -1 peroxygens Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- VPWNQTHUCYMVMZ-UHFFFAOYSA-N 4,4'-sulfonyldiphenol Chemical class C1=CC(O)=CC=C1S(=O)(=O)C1=CC=C(O)C=C1 VPWNQTHUCYMVMZ-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002953 Aphonia Diseases 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 229930185605 Bisphenol Natural products 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 239000004155 Chlorine dioxide Substances 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010048762 Tooth infection Diseases 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229940051881 anilide analgesics and antipyretics Drugs 0.000 description 1
- 150000003931 anilides Chemical class 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 235000019398 chlorine dioxide Nutrition 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- CEJLBZWIKQJOAT-UHFFFAOYSA-N dichloroisocyanuric acid Chemical compound ClN1C(=O)NC(=O)N(Cl)C1=O CEJLBZWIKQJOAT-UHFFFAOYSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000001606 epiglottitis Diseases 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 239000013010 irrigating solution Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012487 rinsing solution Substances 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 229940100890 silver compound Drugs 0.000 description 1
- 150000003379 silver compounds Chemical class 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000002422 sporicide Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000002396 uvula Anatomy 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
Images
Classifications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present disclosure is generally related to inhibiting activity and growth of pathogens, and more specifically, embodiments of the present disclosure relate to the use of hypochlorous acid (HOCl) to inhibit growth of pathogens, including bacteria, virus, yeast, mold, fungus, spore, protozoa or prion.
- HOCl hypochlorous acid
- Antimicrobial medications are commonly used to treat infectious disease. Antimicrobial resistance is a key issue that needs to be taken into account when selecting a therapeutic agent for the treatment of infectious diseases. For example, hospital infections due to multi-resistant bacteria, such as MRSA or Gram-negative multi-resistant bacteria, are serious threats. Although bacterial resistance is a natural phenomenon, the misuse of antimicrobial drugs has accelerated the development of resistance.
- Antiseptics agents are known to destroy or inhibit the growth and development of microorganisms in or on living tissue. Unlike antibiotics that act selectively on a specific target, antiseptics have multiple targets and a broader spectrum of activity, which include bacteria, fungi, viruses, yeast, mold, protozoa, spores, archaea, algae, and even prions.
- the method of treating disease states associated with an increased microbial activity comprises delivering an antiseptic solution of hypochlorous acid to a patient via a respirable delivery method.
- the method of treating disease states associated with an increased microbial activity comprises delivering an antiseptic solution of hypochlorous acid having a pH range of approximately 6.1 to 6.3.
- the method of treating disease states associated with an increased microbial activity comprises placing the aqueous solution of the hypochlorous acid into a reservoir of a nebulizer. In some embodiments, the method of treating disease states associated with an increased microbial activity comprises aerosolizing the aqueous solution of hypochlorous acid into particles. In some embodiments, the hypochlorous acid is aerosolized into particles sized approximately from 0.1 ⁇ m to 99 ⁇ m. In some embodiments, the method of treating disease states associated with an increased microbial activity comprises administering aerosolized particles of the aqueous solution of hypochlorous acid through a mouth piece affixed to the nebulizer into an upper respiratory track of the patient.
- the method of treating disease states associated with an increased microbial activity comprises placing the aqueous solution of the hypochlorous acid within a reservoir of a spray bottle. In some embodiments, the method of treating disease states associated with an increased microbial activity comprises transforming the aqueous solution of the hypochlorous acid into a mist. In some embodiments, the method of treating disease states associated with an increased microbial activity comprises spraying the mist of the aqueous solution of hypochlorous acid into one or more nasal passages and sinuses cavities of the patient.
- FIG. 1 illustrates a perspective view of an antiseptic agent delivery system for administering HOCl comprising a nebulizer, according to an implementation of the disclosure.
- FIG. 2 illustrates a process of administering HOCl using a nebulizer, according to an implementation of the disclosure.
- hypochlorous acid is a weak acid that forms when chlorine dissolves in water, and itself partially dissociates, forming hypochlorite, OCl—. Similar to other chlorine-releasing agents (e.g., sodium hypochlorite, chlorine dioxide, and the N-chloro compounds such as sodium dichloroisocyanurate), aqueous chlorine solution is well known for its antimicrobial, anti-inflammatory, and immunomodulatory properties.
- chlorine-releasing agents e.g., sodium hypochlorite, chlorine dioxide, and the N-chloro compounds such as sodium dichloroisocyanurate
- aqueous solutions containing approximately 30-2500 ppm (0.003% to 0.25%) HOCl are used in a variety of areas including (but not limited to) wound care, as antimicrobial agents, as anti-allergen agents, dental care and there are also significant applications in water treatments, food sanitization, and hard surface disinfection, and cosmetics.
- HOCl is a potent antimicrobial capable of eradicating bacteria including antibiotic-resistant strains, viruses, fungi, and spores.
- HOCl is the active component responsible for pathogen disruption and inactivation by chlorine-releasing agents (CRAB). It is understood that the OCl— ion has little effect compared to undissolved HOCl, as the hypochlorite (OCl—), has only a minute effect compared to undissolved HOCl. Accordingly, the microbicidal effect of HOCl is the greatest when the percentage of undissolved HOCl is highest. In an aqueous solution of HOCl, ranging from approximately pH 4 to pH 7, chlorine exists predominantly as HOCl, whereas above pH 9, ClO— predominates.
- HOCl is a highly active oxidizing agent, its mode of operation comprises destroying and/or deactivating cellular activity of proteins.
- HOCl targets bacteria by chemically linking chlorine atoms to nucleotide bases that disrupt the function of bacterial DNA, impede metabolic pathways in which cells use enzymes to oxidize nutrients, and release energy, and other membrane-associated activities.
- HOCl has also been found to disrupt oxidative phosphorylation and other membrane-associated activity.
- HOCl has been found to inhibit bacterial growth. For example, at 50 mM (2.6 ppm), HOCl completely inhibited the growth of E. coli within 5 minutes, including inhibiting the DNA synthesis by ninety-six percent.
- HOCl Unlike conventional antibiotics, the antimicrobial activity of HOCl is directly toxic to microbial cells, including many Gram-positive and Gram-negative bacteria and their biofilms. HOCl has demonstrated disinfection efficacy against eradication of bacteria, including Acinetobacter baumannii, Bacillus subtilis, Enterobacter cloacae, Enterococcus faecalis, Escherichia coli, Escherichia coli, Escherichia coli, Enterobacter, Klebsiella pneumoniae, Listeria monocytogenes , MRSA ( Staph.
- HOCl possesses viricidal activity properties. For example, it has been demonstrated that HOCl inactivated naked f2 RNA at the same rate as RNA in intact phage, whereas f2 capsid proteins could still adsorb to the host. HOCl has demonstrated disinfection efficacy against eradication of viruses including norovirus, filoviruses such as Ebola, and human coronaviruses like MERS-CoV and SARS, as well as fungi such as Candida and Aspergillus . Further, as a sporicide, HOCl causes the spore coat to detach from the cortex, where further degradation occurs.
- HOCl Both topical and internal applications of HOCl are safe because it is the exact same substance white blood cells in the human body produce to fight infection. Indeed, extensive studies have demonstrated exceptional safety of HOCl.
- Food and Drug Administration has approved preparations of HOCl to be used, e.g., topically for eye infections, tooth infections, nasal decontamination, and the care of surgical incisions. In particular, inhaling the aerosolized form of HOCl has also been shown to causes no adverse effects.
- Embodiments of the technology disclosed herein are directed to antiseptic agent delivery systems in which the antiseptic agent is administered via a pulmonary route as a treatment of infectious diseases caused by microbial (including spores), viral, fungal, allergy-causing agents. Because the inhalation process gives a more direct access to the target organ/cavity than more traditional routes (e.g., topical, oral, intravenous, etc.), the pulmonary administration of HOCl used to inhibit bacterial growth provides a therapeutic approach that may help avoid reduce antimicrobial resistance while alleviating the disease symptoms.
- upper respiratory tract infections caused by one or more bacterial or viral pathogens such as bronchitis, epiglottitis, laryngitis, sinusitis, rhinosinusitis, chronic rhinosinusitis and so on, lung infections, such as pneumonia, may be treated by a pulmonary administration of an antiseptic agent, such as HOCl.
- an antiseptic agent such as HOCl.
- a solution of HOCl may be delivered via the pulmonary route via a number pulmonary delivery devices.
- the HOCl may be delivered via a nebulizer, an aerosolizer, atomizer, and/or any other such pulmonary delivery device.
- a solution of HOCl of low concentration levels and relatively low acidotic pH may be used as a nebulized topical laryngeal, tracheal, and alveolar disinfectant.
- the aqueous solution of HOCl may include a concentration of approximately 0.01 percent of HOCl dissolved in water.
- FIG. 1 depicts an antiseptic agent delivery system for delivering HOCl via the pulmonary route.
- the antiseptic agent delivery system 100 or components/features thereof may be implemented in combination with, or as an alternative to, other systems/features/components described herein, such as those described with reference to other embodiments and figures.
- the antiseptic agent delivery system 100 may additionally be utilized in any of the methods for using such systems/components/features described herein.
- the antiseptic agent delivery system 100 may also be used in various applications and/or permutations, which may or may not be noted in the illustrative embodiments described herein.
- antiseptic agent delivery system 100 may include more or less features/components than those shown in FIG. 1 , in some embodiments.
- the antiseptic agent delivery system 100 is not limited to the size, shape, number of components, etc. specifically shown in FIG. 1 .
- the antiseptic agent delivery system 100 comprises a housing 112 which houses one or more components configured to aerosolize the aqueous antiseptic solution so that it can be administered it in the form of aerosolized particles by being inhaled into lungs.
- the one or more components hosed in housing 112 may include an ultrasonic generator or oscillator, a compressor, or similar components and associated circuitry (not shown) for causing aerosolization.
- the antiseptic agent delivery system 100 comprises a liquid supply reservoir 118 and a mouth piece 110 .
- the aqueous antiseptic solution may be placed within the liquid supply reservoir 118 .
- the aqueous antiseptic solution may include liquid HOCl liquid solution ranging from 0.5 ml to 20 ml placed in the reservoir 118 .
- the one or components housed within housing 112 may cause the aqueous antiseptic solution to be aerosolize the aqueous antiseptic solution.
- the housing 112 may include an inlet (not shown) through which air is supplied under pressure from a compressor (not shown).
- agent delivery system 100 may be configured to use a driving gas flow (typically 0.5 mL/min) to generate aerosol.
- the nebulizers may deliver an approximately equal volume of aerosol during the inhalation phase (i.e., when patient is breathing).
- an oscillator (not shown) may transmit ultrasonic waves through the aqueous antiseptic solution.
- the pressurized air may be directed via an air channel (not shown) into the liquid supply reservoir 118 causing a rapid formation and collapse of bubbles, which then stream toward the surface of the solution and encounter the interface between the solution and air, resulting in a production of a fine mist or aerosol adjacent the solution surface.
- the antiseptic agent delivery system 100 may be configured to carry the aerosol upwardly through a conduit 120 connected to the mouth piece 110 .
- the patient may aspirate the aerosolized aqueous antiseptic solution through the mouth piece 110 .
- the diameter of aerosol particles or droplets may be approximately 1 to 5 microns to ensure the particles or droplets are not likely to be impacted in the airway before they reach the lungs and are not carried out of the lungs again on exhalation without being deposited within the respiratory system structures (e.g., lungs).
- the conduit 120 may be configured to be slightly larger in diameter than an exit port (not shown) within the mouthpiece 110 .
- the conduit 120 By virtue of the conduit 120 being slightly larger in diameter than the air exit port of the mouth piece 100 a small space between the outer surface of the air exit port and the inner surface of the conduit 120 is provided.
- the space may be approximately 0.00254-0.254 mm.
- the space allows fluid from the liquid supply reservoir 118 to proceed upward between the air exit port and the conduit 120 .
- the diameter of the conduit 120 may be adjusted to change the particle size of the mist.
- the housing 112 may include one or more pressure sensors (not shown) configured to detect the pressure within the liquid supply reservoir 118 .
- the one or more pressure sensors may be connected to the inside of the mouth piece 100 .
- the one or more pressure sensors may detect that a patient has inhaled causing the antiseptic agent delivery system 100 to divert pressurized air to an air outlet (not shown).
- the antiseptic agent delivery system 100 may be configured to analyze the pressure changes within the system 100 during a certain number of initial breaths (e.g., first three breaths) to determine an average shape of the breathing pattern. A timed pulse of atomization is commenced upon start of subsequent inspirations such that atomization occurs for the first 50 percent of the inspiration. In some embodiments, the antiseptic agent delivery system 100 may be configured to have a timed pulse of atomization to occur during a period other than 50% of the duration of inspiration. In some embodiments, the antiseptic agent delivery system 100 may be configured to have a predetermined pulse length. For example, the pulse length may be set for each patient by a clinician.
- the housing 112 may include one or more panels (not shown) to operate the one or more components configured to aerosolize the aqueous antiseptic solution.
- the housing 112 may comprise a connector 114 to which a power cable (not shown) may be connected.
- the nebulized HOCl may be delivered using compressor-based jet-nebulizer system.
- a jet nebulizer may be configured with a mechanism to allow the production of aerosol HOCl only when the inhalation airflow exceeds a certain flow rate. By virtue of including the mechanism, the jet nebulizer provides control over the portion of the breath into which the aerosol HOCl is delivered.
- the nebulized HOCl may be delivered using a mesh-based nebulizer system.
- the mesh-based nebulizer may be used to deliver aerosol HOCl based on a breathing-pattern of a patient.
- the mesh-based nebulizer may include one or more sensors configured to monitor inspiratory flow rate and length of the inhalation.
- aerosol HOCl may be pulsed during the first fifty to eighty percent of the inhalation, based on determined specific characteristics of the breathing pattern. The duration of each pulse of aerosol HOCl may be determined by the patient's breathing pattern and varied for each subsequent breath, depending on the preceding breaths.
- the nebulized HOCl may be delivered using an ultrasonic wave nebulizer.
- the ultrasound wave nebulizer may comprise an electronic oscillator and a one or more piezoelectric elements to create an aerosol.
- the electronic oscillator may be configured to generate a high frequency ultrasonic wave, which causes the mechanical vibration of the one or more piezoelectric elements, the one or more piezoelectric elements may be in contact with a compartment used to store an aqueous HOCl solution.
- the one or more piezoelectric elements may vibrate at a high frequency and deliver a vapor mist comprising an aerosolized HOCl.
- illness suspected to be caused by microbial (including spores), viral, fungal, allergy-causing agents may be treated by administering HOCl through use of aerosolized or atomized pulmonary administration.
- Embodiments using this method involve the use of an aerosolizer or an atomizer to aerosolize a liquid HOCl solution for respirable delivery.
- the delivery of the aerosolized HOCl may include one or more of the following operations.
- an aqueous antiseptic solution may be placed in a reservoir of an aerosolizing, atomizing, or similar device.
- the aqueous antiseptic solution comprising HOCl ranging in volume from approximately 0.5 ml to 10 ml may be placed into the reservoir.
- the aqueous antiseptic solution may be aerosolized into particle sizes.
- the aqueous antiseptic solution comprising HOCl may be aerosolized into particles ranging from approximately 0.1 ⁇ m to 99 ⁇ m or larger, in size.
- the aqueous antiseptic solution may be directed into a mouth piece affixed to the device to be aspired by a patient into their upper respiratory track.
- the aerosolized aqueous antiseptic solution comprising HOCl may be aspired for a prescribed duration (e.g., a period ranging from approximately 0.5 min to 30 min. or longer).
- illness suspected to be caused by microbial (including spores), viral, fungal, allergy-causing agents may be treated by administering HOCl through use of aerosolized or atomized administration via patient's nasal sinus passages.
- the delivery of the aerosolized HOCl may include one or more of the following: placing liquid solution ranging from 0.5 ml to 10 ml placed in the reservoir of an aerosolizing, atomizing, or similar device, aerosolizing or atomizing the liquid into particle sizes ranging from approximately 0.1 ⁇ m to 99 ⁇ m or larger, and inserting a nose piece affixed to the device into the nostril(s) for a prescribed duration (e.g., a period ranging from approximately 0.5 min to 10 min, or longer).
- a prescribed duration e.g., a period ranging from approximately 0.5 min to 10 min, or longer.
- illness suspected to be caused by microbial (including spores), viral, fungal, allergy-causing agents may be treated by administering HOCl through use of a nasal spray.
- a spray device comprising a pump and a spray nozzle, may be used to transform the aqueous solution of HOCl into a mist for administering the solution to the nasal passages and sinus cavities.
- the delivery of the mist comprising an aqueous HOCl solution may include one or more of the following: placing an aqueous solution of HOCl ranging from 0.1 ml to 10 ml into a nasal spray bottle adequately suited for nasal use, and administering the mist comprising aqueous solution HOCl into the nasal passages of each nostril via the spray bottle by compressing the spray bottle. For example, approximately one to ten sprays per nostril may be administered into each nostril by compressing the spray bottle.
- the aqueous solution of HOCl may be diluted with one or more diluents. For example, 0.5 ml to 20 ml of saline may be added to the aqueous solution of HOCl.
- illness suspected to be caused microbial including spores
- viral, fungal, allergy-causing agents may be treated by administering HOCl through use of nasal rinsing or irrigation.
- nasal rinses and irrigation systems are used to flush out excess mucus and debris from the nasal passages and sinus cavities, but they can also be used to administer medicated solutions to the nasal passages and sinus cavities.
- the delivery of the aqueous solution of HOCl may include one or more of the following: adding an aqueous solution of HOCl (ranging approximately from approximately 0.1 ml to 10 ml) to a commercially available or prepared nasal rinsing or irrigation solution, and administering the aqueous solution of HOCl to the nasal passages and sinus cavities by rinsing, flushing, irrigating, or otherwise exposing nasal passages and cavities to the combined aqueous solution of HOCl and rinsing or irrigating solution.
- illness suspected to be caused microbial may be treated by administering HOCl through use of an oral rinse solution.
- oral rinses use a liquid solution that is used to swish around the oral cavity, including teeth, gums and tongue to help prevent or treat various oral health conditions and diseases (e.g., gum disease, halitosis, gingivitis, tartar, and so on).
- the aqueous solution of HOCl may be diluted with one or more diluents. For example, approximately 0.5 ml to 20 ml of saline may be added to the aqueous solution of HOCl.
- a particular amount of aqueous solution of HOCl may be placed inside a patient's oral cavity without swallowing. While keeping the lips closed, the patient may make a swishing motion to move the HOCl so that so that the HOCl solution reaches the front and sides of your mouth equally for a prescribed duration (e.g., a period ranging from approximately 0.5 min to 10 min, or longer), repeating it as necessary. Upon completing the oral rinse, the HOCl solution may be spitted out.
- illness suspected to be caused microbial including spores
- viral, fungal, allergy-causing agents may be treated by administering HOCl through use of a gargling solution.
- a particular amount of aqueous solution of HOCl e.g., approximately 5 mL
- the patient may move the liquid within the throat cavity by exhaling through it for a prescribed duration (e.g., a period ranging from approximately 0.5 min to 10 min, or longer), repeating it as necessary.
- the HOCl solution may be spitted out.
- a spray device comprising a spray nozzle, may be used to transform the aqueous solution of HOCl into a mist for administering the solution to the oral cavity and/or throat structures (e.g., oropharynx, larynx, etc.).
- the aqueous solution of HOCl may be diluted with one or more diluents. For example, approximately 0.5 ml to 20 ml of saline may be added to the aqueous solution of HOCl.
- illness suspected to be caused by adverse reactions to one or more medications and/or lifestyle choices may be may be treated by administering HOCl through use of an or oral rinse and/or gargling solution, as described above.
- oral inflammation and/or ulceration e.g., mucositis
- a particular medication e.g., chemotherapy and radiotherapy treatment for cancer
- dehydration e.g., oxygen therapy
- excessive use of alcohol and/or tobacco, and lack of protein in the diet may be treated by placing a particular amount of aqueous solution of HOCl (e.g., approximately 5 mL) may be placed inside a patient's oral cavity without swallowing and used as an oral rinse and/or a gargling.
- the aqueous solution of HOCl may be diluted with one or more diluents. For example, approximately 0.5 ml to 20 ml of saline may be added to the aqueous solution of HOCl.
- the delivery of the mist comprising an aqueous HOCl solution may include one or more of the following: placing an aqueous solution of HOCl ranging from 0.1 ml to 10 ml into a spray bottle adequately suited for oral use, and administering the mist comprising aqueous solution HOCl into the oral cavity and surrounding throat structures via the spray bottle by compressing the spray bottle. For example, approximately one to ten sprays may be administered into the oral cavity by compressing the spray bottle.
- the aqueous solution of HOCl may be diluted with one or more diluents. For example, approximately 0.5 ml to 20 ml of saline may be added to the aqueous solution of HOCl.
- one or more effects of relaxing one or more respiratory structures e.g., uvula, soft palate, etc.
- a sound e.g., snoring
- the HOCl may be administered through the use of a HOCl containing oral rinse solution, a gargling solution, as described above.
- an irritation, inflammation, and/or obstruction of the breathing passages resulting in in a cough reflex and often associated with acute and/or chronic respiratory tract infection may be treated by administering HOCl.
- the HOCl may be administered through the use of a HOCl containing oral rinse solution, a gargling solution, as described above.
- the HOCl solution may be administered by a pulmonary delivery method, as described above.
- an irritation and/or an inflammation of the voice box resulting in loss of voice and/or diminished capacity to produce sound may be treated by administering HOCl.
- the HOCl may be administered through the use of a HOCl containing oral rinse solution, a gargling solution, as described above.
- the HOCl solution may be administered by a pulmonary delivery method, as described above.
- an irritation and/or an inflammation of one or more structures within the nasal cavity and/or throat due to an allergic reaction to one or more allergens may be treated by administering HOCl.
- the HOCl solution may be used to decrease the activity of allergy-causing agents through the use of a HOCl containing nasal spray solution, a nasal rinse or irrigation solution, an oral rinse solution, and/or a gargling solution, as described above.
- the HOCl solution may be administered by a pulmonary delivery method, as described above.
- the HOCl solution may be used to decrease the histamine response which may be elevated during an allergic response to one or more allergens, as previously alluded.
- the HOCl may be administered through the use of a HOCl containing oral rinse solution, a gargling solution, as described above, or a pulmonary delivery method.
- the pH level of the HOCl solution administered through the methods disclosed herein may be pH-neutral because stabilized and/or pH-neutral HOCl is superior in terms of antimicrobial activity to non-stabilized HOCl and acidified bleach, including against hypochlorite-resistant strains.
- the acidotic pH level of the HOCl may be within the range resulting in the highest amount of undissolved HOCl. For example, the acidotic pH level may range from approximately pH 6.1 to approximately pH 6.3.
- illness suspected to be caused by microbial may be treated by administering HOCl through use of a vaping device.
- the vaping device may comprise a cartridge configured to store HOCl solution, and a heating element/atomizer, a microprocessor, a battery, and/or other such similar components.
- the delivery of the vapor solution of HOCl may include one or more of the following: adding an aqueous solution of HOCl (ranging approximately from approximately 0.1 ml to 10 ml) to a cartridge of a vaping device, atomizing the liquid into particle sizes ranging from approximately 0.1 ⁇ m to 99 ⁇ m or larger by the heating element, and breathing the atomized particles through a mouth piece affixed to the device into the upper respiratory track to administer the atomized HOCl for a prescribed duration (e.g., a period ranging from approximately 0.5 min to 30 min. or longer).
- HOCl solution may be heated to a certain temperature (e.g., at or about 100-250° C.) to create an aerosolized vapor.
- illness suspected to be caused by microbial (including spores), viral, fungal, allergy-causing agents may be treated by administering HOCl solution as an agent in an aerial diffusion.
- HOCl solution may be administered as an agent in an aerial diffusion.
- disinfectant properties of HOCl may be delivered via a diffusion device.
- a diffusion device may be configured to volatilize HOCl into the air. The volatilized HOCl may then be inhaled by one or more patients to treat one or more respiratory illness suspected to be caused by microbial (including spores), viral, fungal, allergy-causing agents.
- ophthalmic illnesses suspected to be caused by microbial including spores
- viral, fungal, allergy-causing agents may be treated by administering HOCl solution.
- disinfectant properties of HOCl may be delivered via a dropper or a similar device adapted for delivering solutions into a patient's eye.
- cochlear illnesses suspected to be caused by microbial may be treated by administering HOCl solution.
- disinfectant properties of HOCl may be delivered via be delivered via a dropper or a similar device adapted for delivering solutions into a patient's ears.
- a diffusion device may be configured to volatilize HOCl into the air.
- the volatilized HOCl may then be inhaled by one or more patients to treat one or more respiratory illness suspected to be caused by microbial (including spores), viral, fungal, allergy-causing agents.
- HOCl solution may be administered intravenously and used as a prophylactic solution to defend against a potential microbial (including spores), viral, fungal, allergy-causing agents.
- HOCl solution administered intravenously, may be used to counter one or more types of influenza virus (e.g., H1N1) strains.
Abstract
A method of treating disease states associated with bacteria, a virus, a yeast, a mold, a fungus, a spore, a protozoa or a prion comprising a respiratory, oral, and internal delivery of hypochlorous acid (HOCl) via a nebulizer, an aerosolizer, an spray a spray bottle, an oral rinse, an oral gargle, a vaping device, and a diffuse.
Description
- The present disclosure is generally related to inhibiting activity and growth of pathogens, and more specifically, embodiments of the present disclosure relate to the use of hypochlorous acid (HOCl) to inhibit growth of pathogens, including bacteria, virus, yeast, mold, fungus, spore, protozoa or prion.
- Antimicrobial medications are commonly used to treat infectious disease. Antimicrobial resistance is a key issue that needs to be taken into account when selecting a therapeutic agent for the treatment of infectious diseases. For example, hospital infections due to multi-resistant bacteria, such as MRSA or Gram-negative multi-resistant bacteria, are serious threats. Although bacterial resistance is a natural phenomenon, the misuse of antimicrobial drugs has accelerated the development of resistance.
- Antiseptics agents are known to destroy or inhibit the growth and development of microorganisms in or on living tissue. Unlike antibiotics that act selectively on a specific target, antiseptics have multiple targets and a broader spectrum of activity, which include bacteria, fungi, viruses, yeast, mold, protozoa, spores, archaea, algae, and even prions. Several antiseptic categories exist, including alcohols (ethanol), anilides (triclocarban), biguanides (chlorhexidine), bisphenols (triclosan), chlorine compounds, iodine compounds, silver compounds, peroxygens, and quaternary ammonium compounds. In particular, chlorine-based compounds have been traditionally used for both antiseptic and disinfectant purposes.
- In accordance with one or more embodiments, various features and functionality can be provided to enable or otherwise facilitate delivery of HOCl.
- In some embodiments, the method of treating disease states associated with an increased microbial activity comprises delivering an antiseptic solution of hypochlorous acid to a patient via a respirable delivery method.
- In some embodiments, the method of treating disease states associated with an increased microbial activity comprises delivering an antiseptic solution of hypochlorous acid having a pH range of approximately 6.1 to 6.3.
- In some embodiments, the method of treating disease states associated with an increased microbial activity comprises placing the aqueous solution of the hypochlorous acid into a reservoir of a nebulizer. In some embodiments, the method of treating disease states associated with an increased microbial activity comprises aerosolizing the aqueous solution of hypochlorous acid into particles. In some embodiments, the hypochlorous acid is aerosolized into particles sized approximately from 0.1 μm to 99 μm. In some embodiments, the method of treating disease states associated with an increased microbial activity comprises administering aerosolized particles of the aqueous solution of hypochlorous acid through a mouth piece affixed to the nebulizer into an upper respiratory track of the patient.
- In some embodiments, the method of treating disease states associated with an increased microbial activity comprises placing the aqueous solution of the hypochlorous acid within a reservoir of a spray bottle. In some embodiments, the method of treating disease states associated with an increased microbial activity comprises transforming the aqueous solution of the hypochlorous acid into a mist. In some embodiments, the method of treating disease states associated with an increased microbial activity comprises spraying the mist of the aqueous solution of hypochlorous acid into one or more nasal passages and sinuses cavities of the patient.
- In some embodiments, the method of treating disease states associated with an increased microbial activity caused by at least one of Acinetobacter baumannii, Bacillus subtilis, Enterobacter cloacae, Enterococcus faecalis, Escherichia coli, Escherichia coli, Escherichia coli, Enterobacter, Klebsiella pneumoniae, Listeria monocytogenes, MRSA (Staph. aureus), Polymicrobial biofilm, Proteus vulgaris, Pseudomonas aeruginosa, Salmonella choleraesuis, Shigella flexneri, Staph epidermidis, and Yersinia enterocolitica.
- In some embodiments, the method of treating disease states associated with an increased microbial activity caused by at least one of a bacteria, a virus, a yeast, a mold, a fungus, a spore, a protozoa or a prion.
- FIG. 1 illustrates a perspective view of an antiseptic agent delivery system for administering HOCl comprising a nebulizer, according to an implementation of the disclosure.
- FIG. 2 illustrates a process of administering HOCl using a nebulizer, according to an implementation of the disclosure.
- Hypochlorous acid (HOCl) is a weak acid that forms when chlorine dissolves in water, and itself partially dissociates, forming hypochlorite, OCl—. Similar to other chlorine-releasing agents (e.g., sodium hypochlorite, chlorine dioxide, and the N-chloro compounds such as sodium dichloroisocyanurate), aqueous chlorine solution is well known for its antimicrobial, anti-inflammatory, and immunomodulatory properties.
- Applications of aqueous solutions containing approximately 30-2500 ppm (0.003% to 0.25%) HOCl are used in a variety of areas including (but not limited to) wound care, as antimicrobial agents, as anti-allergen agents, dental care and there are also significant applications in water treatments, food sanitization, and hard surface disinfection, and cosmetics.
- HOCl is a potent antimicrobial capable of eradicating bacteria including antibiotic-resistant strains, viruses, fungi, and spores. In particular, HOCl is the active component responsible for pathogen disruption and inactivation by chlorine-releasing agents (CRAB). It is understood that the OCl— ion has little effect compared to undissolved HOCl, as the hypochlorite (OCl—), has only a minute effect compared to undissolved HOCl. Accordingly, the microbicidal effect of HOCl is the greatest when the percentage of undissolved HOCl is highest. In an aqueous solution of HOCl, ranging from approximately pH 4 to pH 7, chlorine exists predominantly as HOCl, whereas above pH 9, ClO— predominates.
- Because HOCl is a highly active oxidizing agent, its mode of operation comprises destroying and/or deactivating cellular activity of proteins. For example, HOCl targets bacteria by chemically linking chlorine atoms to nucleotide bases that disrupt the function of bacterial DNA, impede metabolic pathways in which cells use enzymes to oxidize nutrients, and release energy, and other membrane-associated activities. Additionally, HOCl has also been found to disrupt oxidative phosphorylation and other membrane-associated activity. Similarly, HOCl has been found to inhibit bacterial growth. For example, at 50 mM (2.6 ppm), HOCl completely inhibited the growth of E. coli within 5 minutes, including inhibiting the DNA synthesis by ninety-six percent. Unlike conventional antibiotics, the antimicrobial activity of HOCl is directly toxic to microbial cells, including many Gram-positive and Gram-negative bacteria and their biofilms. HOCl has demonstrated disinfection efficacy against eradication of bacteria, including Acinetobacter baumannii, Bacillus subtilis, Enterobacter cloacae, Enterococcus faecalis, Escherichia coli, Escherichia coli, Escherichia coli, Enterobacter, Klebsiella pneumoniae, Listeria monocytogenes, MRSA (Staph. aureus), Polymicrobial biofilm, Proteus vulgaris, Pseudomonas aeruginosa, Salmonella choleraesuis, Shigella flexneri, Staph epidermidis, and Yersinia enterocolitica.
- Additionally, HOCl possesses viricidal activity properties. For example, it has been demonstrated that HOCl inactivated naked f2 RNA at the same rate as RNA in intact phage, whereas f2 capsid proteins could still adsorb to the host. HOCl has demonstrated disinfection efficacy against eradication of viruses including norovirus, filoviruses such as Ebola, and human coronaviruses like MERS-CoV and SARS, as well as fungi such as Candida and Aspergillus. Further, as a sporicide, HOCl causes the spore coat to detach from the cortex, where further degradation occurs.
- Both topical and internal applications of HOCl are safe because it is the exact same substance white blood cells in the human body produce to fight infection. Indeed, extensive studies have demonstrated exceptional safety of HOCl. The Food and Drug Administration (FDA) has approved preparations of HOCl to be used, e.g., topically for eye infections, tooth infections, nasal decontamination, and the care of surgical incisions. In particular, inhaling the aerosolized form of HOCl has also been shown to causes no adverse effects.
- The advent of antibiotics and other area disinfectants led to a reduction in environmental use of HOCl. However, widespread use of antibiotic agents led to antimicrobial resistance. Accordingly, an urgent need to optimize currently available anti-infectious therapies to overcome drug resistance exists.
- Embodiments of the technology disclosed herein are directed to antiseptic agent delivery systems in which the antiseptic agent is administered via a pulmonary route as a treatment of infectious diseases caused by microbial (including spores), viral, fungal, allergy-causing agents. Because the inhalation process gives a more direct access to the target organ/cavity than more traditional routes (e.g., topical, oral, intravenous, etc.), the pulmonary administration of HOCl used to inhibit bacterial growth provides a therapeutic approach that may help avoid reduce antimicrobial resistance while alleviating the disease symptoms. For example, upper respiratory tract infections caused by one or more bacterial or viral pathogens such as bronchitis, epiglottitis, laryngitis, sinusitis, rhinosinusitis, chronic rhinosinusitis and so on, lung infections, such as pneumonia, may be treated by a pulmonary administration of an antiseptic agent, such as HOCl.
- In some embodiments, a solution of HOCl may be delivered via the pulmonary route via a number pulmonary delivery devices. For example, the HOCl may be delivered via a nebulizer, an aerosolizer, atomizer, and/or any other such pulmonary delivery device. For example, a solution of HOCl of low concentration levels and relatively low acidotic pH may be used as a nebulized topical laryngeal, tracheal, and alveolar disinfectant. In some embodiments, the aqueous solution of HOCl may include a concentration of approximately 0.01 percent of HOCl dissolved in water.
- FIG. 1 depicts an antiseptic agent delivery system for delivering HOCl via the pulmonary route. The antiseptic agent delivery system 100 or components/features thereof may be implemented in combination with, or as an alternative to, other systems/features/components described herein, such as those described with reference to other embodiments and figures. The antiseptic agent delivery system 100 may additionally be utilized in any of the methods for using such systems/components/features described herein. The antiseptic agent delivery system 100 may also be used in various applications and/or permutations, which may or may not be noted in the illustrative embodiments described herein. For instance, antiseptic agent delivery system 100 may include more or less features/components than those shown in FIG. 1, in some embodiments. Moreover, the antiseptic agent delivery system 100 is not limited to the size, shape, number of components, etc. specifically shown in FIG. 1.
- As shown in FIG. 1, the antiseptic agent delivery system 100 comprises a housing 112 which houses one or more components configured to aerosolize the aqueous antiseptic solution so that it can be administered it in the form of aerosolized particles by being inhaled into lungs. For example, the one or more components hosed in housing 112 may include an ultrasonic generator or oscillator, a compressor, or similar components and associated circuitry (not shown) for causing aerosolization.
- Further, the antiseptic agent delivery system 100 comprises a liquid supply reservoir 118 and a mouth piece 110. In some embodiments, the aqueous antiseptic solution may be placed within the liquid supply reservoir 118. For example, the aqueous antiseptic solution may include liquid HOCl liquid solution ranging from 0.5 ml to 20 ml placed in the reservoir 118.
- In some embodiments, the one or components housed within housing 112 may cause the aqueous antiseptic solution to be aerosolize the aqueous antiseptic solution. For example, the housing 112 may include an inlet (not shown) through which air is supplied under pressure from a compressor (not shown). In some embodiments, agent delivery system 100 may be configured to use a driving gas flow (typically 0.5 mL/min) to generate aerosol. For example, the nebulizers may deliver an approximately equal volume of aerosol during the inhalation phase (i.e., when patient is breathing). In other embodiments, an oscillator (not shown) may transmit ultrasonic waves through the aqueous antiseptic solution.
- In some embodiments, the pressurized air may be directed via an air channel (not shown) into the liquid supply reservoir 118 causing a rapid formation and collapse of bubbles, which then stream toward the surface of the solution and encounter the interface between the solution and air, resulting in a production of a fine mist or aerosol adjacent the solution surface.
- In some embodiments, the antiseptic agent delivery system 100 may be configured to carry the aerosol upwardly through a conduit 120 connected to the mouth piece 110. The patient may aspirate the aerosolized aqueous antiseptic solution through the mouth piece 110. In some embodiments, the diameter of aerosol particles or droplets may be approximately 1 to 5 microns to ensure the particles or droplets are not likely to be impacted in the airway before they reach the lungs and are not carried out of the lungs again on exhalation without being deposited within the respiratory system structures (e.g., lungs).
- In some embodiments, the conduit 120 may be configured to be slightly larger in diameter than an exit port (not shown) within the mouthpiece 110. By virtue of the conduit 120 being slightly larger in diameter than the air exit port of the mouth piece 100 a small space between the outer surface of the air exit port and the inner surface of the conduit 120 is provided. For example, the space may be approximately 0.00254-0.254 mm. In some embodiments, the space allows fluid from the liquid supply reservoir 118 to proceed upward between the air exit port and the conduit 120. In some embodiments, The diameter of the conduit 120 may be adjusted to change the particle size of the mist.
- In some embodiments, the housing 112 may include one or more pressure sensors (not shown) configured to detect the pressure within the liquid supply reservoir 118. In some embodiments, the one or more pressure sensors may be connected to the inside of the mouth piece 100. In some embodiments, the one or more pressure sensors may detect that a patient has inhaled causing the antiseptic agent delivery system 100 to divert pressurized air to an air outlet (not shown).
- In some embodiments, the antiseptic agent delivery system 100 may be configured to analyze the pressure changes within the system 100 during a certain number of initial breaths (e.g., first three breaths) to determine an average shape of the breathing pattern. A timed pulse of atomization is commenced upon start of subsequent inspirations such that atomization occurs for the first 50 percent of the inspiration. In some embodiments, the antiseptic agent delivery system 100 may be configured to have a timed pulse of atomization to occur during a period other than 50% of the duration of inspiration. In some embodiments, the antiseptic agent delivery system 100 may be configured to have a predetermined pulse length. For example, the pulse length may be set for each patient by a clinician.
- In some embodiments, the housing 112 may include one or more panels (not shown) to operate the one or more components configured to aerosolize the aqueous antiseptic solution. In some embodiments, the housing 112 may comprise a connector 114 to which a power cable (not shown) may be connected.
- In some embodiments, the nebulized HOCl may be delivered using compressor-based jet-nebulizer system. For example, a jet nebulizer may be configured with a mechanism to allow the production of aerosol HOCl only when the inhalation airflow exceeds a certain flow rate. By virtue of including the mechanism, the jet nebulizer provides control over the portion of the breath into which the aerosol HOCl is delivered.
- In some embodiments, the nebulized HOCl may be delivered using a mesh-based nebulizer system. In some embodiments, the mesh-based nebulizer may be used to deliver aerosol HOCl based on a breathing-pattern of a patient. For example, the mesh-based nebulizer may include one or more sensors configured to monitor inspiratory flow rate and length of the inhalation. In some embodiments, aerosol HOCl may be pulsed during the first fifty to eighty percent of the inhalation, based on determined specific characteristics of the breathing pattern. The duration of each pulse of aerosol HOCl may be determined by the patient's breathing pattern and varied for each subsequent breath, depending on the preceding breaths.
- In some embodiments, the nebulized HOCl may be delivered using an ultrasonic wave nebulizer. For example, the ultrasound wave nebulizer may comprise an electronic oscillator and a one or more piezoelectric elements to create an aerosol. The electronic oscillator may be configured to generate a high frequency ultrasonic wave, which causes the mechanical vibration of the one or more piezoelectric elements, the one or more piezoelectric elements may be in contact with a compartment used to store an aqueous HOCl solution. The one or more piezoelectric elements may vibrate at a high frequency and deliver a vapor mist comprising an aerosolized HOCl.
- In some embodiments, illness suspected to be caused by microbial (including spores), viral, fungal, allergy-causing agents may be treated by administering HOCl through use of aerosolized or atomized pulmonary administration. Embodiments using this method involve the use of an aerosolizer or an atomizer to aerosolize a liquid HOCl solution for respirable delivery. For example, and as illustrated in FIG. 2, the delivery of the aerosolized HOCl may include one or more of the following operations. In an operation 202, an aqueous antiseptic solution may be placed in a reservoir of an aerosolizing, atomizing, or similar device. For example, the aqueous antiseptic solution comprising HOCl ranging in volume from approximately 0.5 ml to 10 ml may be placed into the reservoir. In an operation 204, the aqueous antiseptic solution may be aerosolized into particle sizes. For example, the aqueous antiseptic solution comprising HOCl may be aerosolized into particles ranging from approximately 0.1 μm to 99 μm or larger, in size. In an operation 206, the aqueous antiseptic solution may be directed into a mouth piece affixed to the device to be aspired by a patient into their upper respiratory track. For example, the aerosolized aqueous antiseptic solution comprising HOCl may be aspired for a prescribed duration (e.g., a period ranging from approximately 0.5 min to 30 min. or longer).
- In some embodiments, illness suspected to be caused by microbial (including spores), viral, fungal, allergy-causing agents may be treated by administering HOCl through use of aerosolized or atomized administration via patient's nasal sinus passages. For example, the delivery of the aerosolized HOCl may include one or more of the following: placing liquid solution ranging from 0.5 ml to 10 ml placed in the reservoir of an aerosolizing, atomizing, or similar device, aerosolizing or atomizing the liquid into particle sizes ranging from approximately 0.1 μm to 99 μm or larger, and inserting a nose piece affixed to the device into the nostril(s) for a prescribed duration (e.g., a period ranging from approximately 0.5 min to 10 min, or longer).
- In some embodiments, illness suspected to be caused by microbial (including spores), viral, fungal, allergy-causing agents may be treated by administering HOCl through use of a nasal spray. For example, a spray device comprising a pump and a spray nozzle, may be used to transform the aqueous solution of HOCl into a mist for administering the solution to the nasal passages and sinus cavities. In some embodiments, the delivery of the mist comprising an aqueous HOCl solution may include one or more of the following: placing an aqueous solution of HOCl ranging from 0.1 ml to 10 ml into a nasal spray bottle adequately suited for nasal use, and administering the mist comprising aqueous solution HOCl into the nasal passages of each nostril via the spray bottle by compressing the spray bottle. For example, approximately one to ten sprays per nostril may be administered into each nostril by compressing the spray bottle. In some embodiments, the aqueous solution of HOCl may be diluted with one or more diluents. For example, 0.5 ml to 20 ml of saline may be added to the aqueous solution of HOCl.
- In some embodiments, illness suspected to be caused microbial (including spores), viral, fungal, allergy-causing agents may be treated by administering HOCl through use of nasal rinsing or irrigation. Generally, nasal rinses and irrigation systems are used to flush out excess mucus and debris from the nasal passages and sinus cavities, but they can also be used to administer medicated solutions to the nasal passages and sinus cavities. In some embodiments, the delivery of the aqueous solution of HOCl may include one or more of the following: adding an aqueous solution of HOCl (ranging approximately from approximately 0.1 ml to 10 ml) to a commercially available or prepared nasal rinsing or irrigation solution, and administering the aqueous solution of HOCl to the nasal passages and sinus cavities by rinsing, flushing, irrigating, or otherwise exposing nasal passages and cavities to the combined aqueous solution of HOCl and rinsing or irrigating solution.
- In some embodiments, illness suspected to be caused microbial (including spores), viral, fungal, allergy-causing agents may be treated by administering HOCl through use of an oral rinse solution. Generally, oral rinses use a liquid solution that is used to swish around the oral cavity, including teeth, gums and tongue to help prevent or treat various oral health conditions and diseases (e.g., gum disease, halitosis, gingivitis, tartar, and so on). In some embodiments, the aqueous solution of HOCl may be diluted with one or more diluents. For example, approximately 0.5 ml to 20 ml of saline may be added to the aqueous solution of HOCl. In some embodiments, a particular amount of aqueous solution of HOCl (e.g., approximately 5 mL) may be placed inside a patient's oral cavity without swallowing. While keeping the lips closed, the patient may make a swishing motion to move the HOCl so that so that the HOCl solution reaches the front and sides of your mouth equally for a prescribed duration (e.g., a period ranging from approximately 0.5 min to 10 min, or longer), repeating it as necessary. Upon completing the oral rinse, the HOCl solution may be spitted out.
- In some embodiments, illness suspected to be caused microbial (including spores), viral, fungal, allergy-causing agents may be treated by administering HOCl through use of a gargling solution. For example, a particular amount of aqueous solution of HOCl (e.g., approximately 5 mL) may be placed inside a patient's oral cavity without swallowing. While keeping the lips and teeth slightly apart and tilting the head slightly backwards, the patient may move the liquid within the throat cavity by exhaling through it for a prescribed duration (e.g., a period ranging from approximately 0.5 min to 10 min, or longer), repeating it as necessary. Upon completing the gargling, the HOCl solution may be spitted out. In some embodiments a spray device comprising a spray nozzle, may be used to transform the aqueous solution of HOCl into a mist for administering the solution to the oral cavity and/or throat structures (e.g., oropharynx, larynx, etc.). In some embodiments, the aqueous solution of HOCl may be diluted with one or more diluents. For example, approximately 0.5 ml to 20 ml of saline may be added to the aqueous solution of HOCl.
- In some embodiments, illness suspected to be caused by adverse reactions to one or more medications and/or lifestyle choices may be may be treated by administering HOCl through use of an or oral rinse and/or gargling solution, as described above. For example, oral inflammation and/or ulceration (e.g., mucositis) which may arise as an adverse effect to a particular medication (e.g., chemotherapy and radiotherapy treatment for cancer) or due to dehydration, poor mouth care, oxygen therapy, excessive use of alcohol and/or tobacco, and lack of protein in the diet may be treated by placing a particular amount of aqueous solution of HOCl (e.g., approximately 5 mL) may be placed inside a patient's oral cavity without swallowing and used as an oral rinse and/or a gargling. In some embodiments, the aqueous solution of HOCl may be diluted with one or more diluents. For example, approximately 0.5 ml to 20 ml of saline may be added to the aqueous solution of HOCl.
- In some embodiments, the delivery of the mist comprising an aqueous HOCl solution may include one or more of the following: placing an aqueous solution of HOCl ranging from 0.1 ml to 10 ml into a spray bottle adequately suited for oral use, and administering the mist comprising aqueous solution HOCl into the oral cavity and surrounding throat structures via the spray bottle by compressing the spray bottle. For example, approximately one to ten sprays may be administered into the oral cavity by compressing the spray bottle. In some embodiments, the aqueous solution of HOCl may be diluted with one or more diluents. For example, approximately 0.5 ml to 20 ml of saline may be added to the aqueous solution of HOCl.
- In some embodiments, one or more effects of relaxing one or more respiratory structures (e.g., uvula, soft palate, etc.) resulting in a sound (e.g., snoring) due to their vibrations during sleep may be treated by administering HOCl. For example, the HOCl may be administered through the use of a HOCl containing oral rinse solution, a gargling solution, as described above.
- In some embodiments, an irritation, inflammation, and/or obstruction of the breathing passages resulting in in a cough reflex and often associated with acute and/or chronic respiratory tract infection may be treated by administering HOCl. For example, the HOCl may be administered through the use of a HOCl containing oral rinse solution, a gargling solution, as described above. In some embodiments, the HOCl solution may be administered by a pulmonary delivery method, as described above.
- In some embodiments, an irritation and/or an inflammation of the voice box resulting in loss of voice and/or diminished capacity to produce sound (e.g., laryngitis) may be treated by administering HOCl. For example, the HOCl may be administered through the use of a HOCl containing oral rinse solution, a gargling solution, as described above. In some embodiments, the HOCl solution may be administered by a pulmonary delivery method, as described above.
- In some embodiments, an irritation and/or an inflammation of one or more structures within the nasal cavity and/or throat due to an allergic reaction to one or more allergens, such as pet dander, dust, mites, pollen and mold, may be treated by administering HOCl. For example, the HOCl solution may be used to decrease the activity of allergy-causing agents through the use of a HOCl containing nasal spray solution, a nasal rinse or irrigation solution, an oral rinse solution, and/or a gargling solution, as described above. In some embodiments, the HOCl solution may be administered by a pulmonary delivery method, as described above. Alternatively, the HOCl solution may be used to decrease the histamine response which may be elevated during an allergic response to one or more allergens, as previously alluded. For example, the HOCl may be administered through the use of a HOCl containing oral rinse solution, a gargling solution, as described above, or a pulmonary delivery method.
- In some embodiments, the pH level of the HOCl solution administered through the methods disclosed herein may be pH-neutral because stabilized and/or pH-neutral HOCl is superior in terms of antimicrobial activity to non-stabilized HOCl and acidified bleach, including against hypochlorite-resistant strains. In some embodiments, the acidotic pH level of the HOCl may be within the range resulting in the highest amount of undissolved HOCl. For example, the acidotic pH level may range from approximately pH 6.1 to approximately pH 6.3.
- In some embodiments, illness suspected to be caused by microbial (including spores), viral, fungal, allergy-causing agents may be treated by administering HOCl through use of a vaping device. The vaping device may comprise a cartridge configured to store HOCl solution, and a heating element/atomizer, a microprocessor, a battery, and/or other such similar components. In some embodiments, the delivery of the vapor solution of HOCl may include one or more of the following: adding an aqueous solution of HOCl (ranging approximately from approximately 0.1 ml to 10 ml) to a cartridge of a vaping device, atomizing the liquid into particle sizes ranging from approximately 0.1 μm to 99 μm or larger by the heating element, and breathing the atomized particles through a mouth piece affixed to the device into the upper respiratory track to administer the atomized HOCl for a prescribed duration (e.g., a period ranging from approximately 0.5 min to 30 min. or longer). In some embodiments, HOCl solution may be heated to a certain temperature (e.g., at or about 100-250° C.) to create an aerosolized vapor.
- In some embodiments, illness suspected to be caused by microbial (including spores), viral, fungal, allergy-causing agents may be treated by administering HOCl solution as an agent in an aerial diffusion. For example, disinfectant properties of HOCl may be delivered via a diffusion device. In some embodiments a diffusion device may be configured to volatilize HOCl into the air. The volatilized HOCl may then be inhaled by one or more patients to treat one or more respiratory illness suspected to be caused by microbial (including spores), viral, fungal, allergy-causing agents.
- In some embodiments, ophthalmic illnesses suspected to be caused by microbial (including spores), viral, fungal, allergy-causing agents may be treated by administering HOCl solution. For example, disinfectant properties of HOCl may be delivered via a dropper or a similar device adapted for delivering solutions into a patient's eye.
- In some embodiments, cochlear illnesses suspected to be caused by microbial (including spores), viral, fungal, allergy-causing agents may be treated by administering HOCl solution. For example, disinfectant properties of HOCl may be delivered via be delivered via a dropper or a similar device adapted for delivering solutions into a patient's ears.
- In some embodiments a diffusion device may be configured to volatilize HOCl into the air. The volatilized HOCl may then be inhaled by one or more patients to treat one or more respiratory illness suspected to be caused by microbial (including spores), viral, fungal, allergy-causing agents.
- In some embodiments, HOCl solution may be administered intravenously and used as a prophylactic solution to defend against a potential microbial (including spores), viral, fungal, allergy-causing agents. For example, HOCl solution, administered intravenously, may be used to counter one or more types of influenza virus (e.g., H1N1) strains.
- Although the disclosed technology is described above in terms of various exemplary embodiments and implementations, it should be understood that the various features, aspects and functionality described in one or more of the individual embodiments are not limited in their applicability to the particular embodiment with which they are described, but instead can be applied, alone or in various combinations, to one or more of the other embodiments of the disclosed technology, whether or not such embodiments are described and whether or not such features are presented as being a part of a described embodiment. Thus, the breadth and scope of the technology disclosed herein should not be limited by any of the above-described exemplary embodiments.
- Terms and phrases used in this document, and variations thereof, unless otherwise expressly stated, should be construed as open ended as opposed to limiting. As examples of the foregoing: the term “including” should be read as meaning “including, without limitation” or the like; the term “example” is used to provide exemplary instances of the item in discussion, not an exhaustive or limiting list thereof; the terms “a” or “an” should be read as meaning “at least one,” “one or more” or the like; and adjectives such as “conventional,” “traditional,” “normal,” “standard,” “known” and terms of similar meaning should not be construed as limiting the item described to a given time period or to an item available as of a given time, but instead should be read to encompass conventional, traditional, normal, or standard technologies that may be available or known now or at any time in the future. Likewise, where this document refers to technologies that would be apparent or known to one of ordinary skill in the art, such technologies encompass those apparent or known to the skilled artisan now or at any time in the future.
- The presence of broadening words and phrases such as “one or more,” “at least,” “but not limited to” or other like phrases in some instances shall not be read to mean that the narrower case is intended or required in instances where such broadening phrases may be absent.
- Additionally, the various embodiments set forth herein are described in terms of exemplary block diagrams, flow charts and other illustrations. As will become apparent to one of ordinary skill in the art after reading this document, the illustrated embodiments and their various alternatives can be implemented without confinement to the illustrated examples. For example, block diagrams and their accompanying description should not be construed as mandating a particular architecture or configuration.
Claims (7)
1. A method of treating disease states associated with an increased microbial activity, the method comprising:
delivering an aqueous antiseptic solution to a patient, wherein the antiseptic solution is adapted for respirable delivery, comprising the steps of:
administering the atomized particles of the aqueous antiseptic solution through a mouth piece affixed to the vaping device into the upper respiratory track for a prescribed duration;
wherein the aqueous antiseptic solution comprises a solution of hypochlorous acid heated to approximately 100-250° C. and having a pH range of approximately 6.1 to 6.3.
2. (canceled)
3. (canceled)
4. The method of claim 3, wherein the particles range in size approximately from 0.1 μm to 99 μm.
5. (canceled)
6. The method of claim 1, wherein the increased microbial activity is caused by at least one of Acinetobacter baumannii, Bacillus subtilis, Enterobacter cloacae, Enterococcus faecalis, Escherichia coli, Escherichia coli, Enterobacter, Klebsiella pneumoniae, Listeria monocytogenes, MRSA (Staph. aureus), Polymicrobial biofilm, Proteus vulgaris, Pseudomonas aeruginosa, Salmonella choleraesuis, Shigella flexneri, Staph epidermidis, and Yersinia enterocolitica.
7. The method of claim 1, wherein the increased microbial activity is caused by at least one of a bacteria, a virus, a yeast, a mold, a fungus, a spore, a protozoa or a prion.
US16/293,551 2019-03-05 2019-03-05 Inhibiting viral and bacterial activity using low concentration hypochlorous acid solutions Abandoned US20200281969A1 (en)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
US16/293,551 US20200281969A1 (en) | 2019-03-05 | 2019-03-05 | Inhibiting viral and bacterial activity using low concentration hypochlorous acid solutions |
US16/503,397 US20200281970A1 (en) | 2019-03-05 | 2019-07-03 | Method of treating gingivitis using low concentration hypochlorous acid solutions |
PCT/US2020/021268 WO2020181138A1 (en) | 2019-03-05 | 2020-03-05 | Inhibiting viral and bacterial activity using low concentration hypochlorous acid solutions |
US16/833,209 US20200281971A1 (en) | 2019-03-05 | 2020-03-27 | Inhibiting viral and bacterial activity using low concentration hypochlorous acid solutions |
US17/179,251 US20210177892A1 (en) | 2019-03-05 | 2021-02-18 | Prevention and treatment of infectious disease using low concentration hypochlorous acid solutions |
US17/518,452 US20220054539A1 (en) | 2019-03-05 | 2021-11-03 | Disinfection and deodorizing of pap equipment using low concentration hypochlorous acid solutions |
US17/850,003 US20220323489A1 (en) | 2019-03-05 | 2022-06-27 | Hypochlorous acid solutions for the treatment of drug resistant pneumonia and tuberculosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
US16/293,551 US20200281969A1 (en) | 2019-03-05 | 2019-03-05 | Inhibiting viral and bacterial activity using low concentration hypochlorous acid solutions |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
US16/503,397 Continuation-In-Part US20200281970A1 (en) | 2019-03-05 | 2019-07-03 | Method of treating gingivitis using low concentration hypochlorous acid solutions |
US16/833,209 Continuation US20200281971A1 (en) | 2019-03-05 | 2020-03-27 | Inhibiting viral and bacterial activity using low concentration hypochlorous acid solutions |
Publications (1)
Publication Number | Publication Date |
US20200281969A1 true US20200281969A1 (en) | 2020-09-10 |
Family
ID=72336736
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
US16/293,551 Abandoned US20200281969A1 (en) | 2019-03-05 | 2019-03-05 | Inhibiting viral and bacterial activity using low concentration hypochlorous acid solutions |
US16/503,397 Abandoned US20200281970A1 (en) | 2019-03-05 | 2019-07-03 | Method of treating gingivitis using low concentration hypochlorous acid solutions |
US16/833,209 Abandoned US20200281971A1 (en) | 2019-03-05 | 2020-03-27 | Inhibiting viral and bacterial activity using low concentration hypochlorous acid solutions |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
US16/503,397 Abandoned US20200281970A1 (en) | 2019-03-05 | 2019-07-03 | Method of treating gingivitis using low concentration hypochlorous acid solutions |
US16/833,209 Abandoned US20200281971A1 (en) | 2019-03-05 | 2020-03-27 | Inhibiting viral and bacterial activity using low concentration hypochlorous acid solutions |
Country Status (2)
Country | Link |
US (3) | |
WO (1) |
Cited By (5)
* Cited by examiner, † Cited by third party
Publication number | Priority date | Publication date | Assignee | Title |
2019-08-22 | 2022-04-15 | 四川大学 | Application of pseudomonas aeruginosa vaccine in respiratory system diseases | |
2020-12-02 | 2022-06-03 | 全鹏科技股份有限公司 | Disinfecting and sterilizing liquid, its production method and use | |
2021-02-27 | 2022-09-01 | Reinaldo Faget-Mora | Fogonazo Solution | |
2020-05-01 | 2023-05-09 | Tygrus, LLC | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses | |
2020-05-01 | 2023-11-28 | Tygrus, LLC | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses |
Families Citing this family (2)
* Cited by examiner, † Cited by third party
Publication number | Priority date | Publication date | Assignee | Title |
2020-04-03 | 2023-05-18 | Phase One Health, Llc | Hypochlorous acid solutions and methods of use | |
2021-07-14 | 2021-08-25 | Hypo Stream Ltd | Treatment of respiratory conditions |
Family Cites Families (4)
* Cited by examiner, † Cited by third party
Publication number | Priority date | Publication date | Assignee | Title |
2006-01-20 | 2007-08-23 | Oculus Innovative Sciences, Inc. | Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution | |
2007-01-16 | 2018-06-19 | Realm Therapeutics, Inc. | Methods and compositions for treating inflammatory disorders | |
2007-01-16 | 2008-07-24 | Puricore, Inc. | Methods and compositions for treating conditions associated with infection and/or inflammation | |
2008-12-18 | 2011-09-29 | Nevoa Solutions | Treatment or prevention of viral infection by chlorination |
- 2019
- 2019-03-05 US US16/293,551 patent/US20200281969A1/en not_active Abandoned
- 2019-07-03 US US16/503,397 patent/US20200281970A1/en not_active Abandoned
- 2020
- 2020-03-05 WO PCT/US2020/021268 patent/WO2020181138A1/en active Application Filing
- 2020-03-27 US US16/833,209 patent/US20200281971A1/en not_active Abandoned
Cited By (6)
* Cited by examiner, † Cited by third party
Publication number | Priority date | Publication date | Assignee | Title |
2019-08-22 | 2022-04-15 | 四川大学 | Application of pseudomonas aeruginosa vaccine in respiratory system diseases | |
2020-05-01 | 2023-05-09 | Tygrus, LLC | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses | |
2020-05-01 | 2023-11-28 | Tygrus, LLC | Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses | |
2020-12-02 | 2022-06-03 | 全鹏科技股份有限公司 | Disinfecting and sterilizing liquid, its production method and use | |
2021-02-27 | 2022-09-01 | Reinaldo Faget-Mora | Fogonazo Solution | |
2021-02-27 | 2024-04-16 | Reinaldo Foget Mora | Fogonazo solution |
Also Published As
Publication number | Publication date |
2020-09-10 | |
2020-09-10 | |
2020-09-10 |
Similar Documents
Publication | Publication Date | Title |
2020-09-10 | Inhibiting viral and bacterial activity using low concentration hypochlorous acid solutions | |
2017-08-01 | Aerosol inhalation device | |
2012-12-25 | Methods and systems for operating an aerosol generator | |
2014-07-22 | Antimicrobial solutions containing dichlorine monoxide and methods of making and using the same | |
2020-11-11 | Methods for the treatment of lung diseases with mast cell stabilizers | |
2013-06-20 | Method for operating aerosol delivery device and aerosol delivery device | |
2019-02-12 | Method of treating sinusitis, including chronic sinusitis | |
2020-11-20 | Method for preventing and treating viral respiratory diseases by atomizing iodine-containing disinfectant | |
2023-01-09 | Compositions and methods for treating biofilms | |
2021-11-18 | Compositions and methods to disinfect, treat and prevent microbial infections | |
2022-04-14 | Compositions and methods to disinfect, treat and prevent microbial infections | |
2015-12-24 | Formulations of amikacin and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis | |
2022-02-24 | Disinfection and deodorizing of pap equipment using low concentration hypochlorous acid solutions | |
2021-08-19 | Inhalable compositions for use in the treatment of lung diseases | |
2016-11-04 | Aminoglycoside and fosfomycin combination formulation with improved chemical properties | |
2006-09-21 | Chemical composition and method for cold and sinus relief | |
2021-06-17 | Prevention and treatment of infectious disease using low concentration hypochlorous acid solutions | |
2008-01-03 | Medical irrigating system and antimicrobial substance used therein | |
2022-10-13 | Hypochlorous acid solutions for the treatment of drug resistant pneumonia and tuberculosis | |
2022-01-13 | Compositions and methods to disinfect, treat and prevent microbial infections | |
2022-11-03 | Systems and methods of using an ultrasonic fogger to distribute an antiseptic solution | |
2023-07-01 | An aqueous pharmaceutical composition and mobile drug delivery device for preventing and treating bacterial and viral respiratory diseases and thereof | |
2021-11-23 | Process of using chlorine dioxide for the attenuation and/or treatment of Coronavirus diseases such as COVID-19 and disabling, treating or attenuating the SARS CoV-2 virus, and its future infective variants | |
2024-04-18 | Compositions and methods for treatment and prevention of pathogens | |
2024-02-29 | Formulations of a Prophylactic Nasal Spray and Methods of Use and Manufacture Thereof |
Legal Events
Date | Code | Title | Description |
2019-03-25 | AS | Assignment | Owner name: WONDER SPRAY, LLC, CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BURD, JOHN;REEL/FRAME:048693/0588
Effective date: 20190325 |
2020-09-08 | STPP | Information on status: patent application and granting procedure in general | Free format text: FINAL REJECTION MAILED |
2021-02-16 | STPP | Information on status: patent application and granting procedure in general | Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
2021-03-17 | STPP | Information on status: patent application and granting procedure in general | Free format text: NON FINAL ACTION MAILED |
2021-08-04 | STPP | Information on status: patent application and granting procedure in general | Free format text: FINAL REJECTION MAILED |
2022-01-05 | STPP | Information on status: patent application and granting procedure in general | Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
2022-01-19 | STPP | Information on status: patent application and granting procedure in general | Free format text: NON FINAL ACTION MAILED |
2022-05-19 | STPP | Information on status: patent application and granting procedure in general | Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
2022-05-25 | STPP | Information on status: patent application and granting procedure in general | Free format text: FINAL REJECTION MAILED |
2022-08-11 | STPP | Information on status: patent application and granting procedure in general | Free format text: ADVISORY ACTION MAILED |
2022-08-25 | STPP | Information on status: patent application and granting procedure in general | Free format text: NON FINAL ACTION MAILED |
2022-11-07 | STPP | Information on status: patent application and granting procedure in general | Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
2022-11-23 | STPP | Information on status: patent application and granting procedure in general | Free format text: FINAL REJECTION MAILED |
2023-05-08 | STCV | Information on status: appeal procedure | Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED |
2023-07-12 | STCV | Information on status: appeal procedure | Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS |
2023-09-01 | STCV | Information on status: appeal procedure | Free format text: BOARD OF APPEALS DECISION RENDERED |
2023-11-13 | STCB | Information on status: application discontinuation | Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |